• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

综述文章:溃疡性结肠炎缓解的定义。

Review article: defining remission in ulcerative colitis.

机构信息

Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.

出版信息

Aliment Pharmacol Ther. 2011 Jul;34(2):113-24. doi: 10.1111/j.1365-2036.2011.04701.x. Epub 2011 May 25.

DOI:10.1111/j.1365-2036.2011.04701.x
PMID:21615435
Abstract

BACKGROUND

There is no international agreement on scoring systems used to measure disease activity in ulcerative colitis, nor is there a validated definition for disease remission.

AIM

To review the principles and components for defining remission in ulcerative colitis and propose a definition that will help improve patient outcomes.

METHODS

A review of current standards of remission from the perspective of clinical trials, guidelines, clinical practice and patients was conducted by the authors. Selected literature focused on the components of a definition of remission, the utility of a definition and treatment strategies, based on current definitions.

RESULTS

Different definitions of remission affect the assessment of outcome and make it difficult to compare trials. In the clinic, endoscopy is rarely used to confirm remission, because mucosal healing has only recently begun to be related to the duration of subsequent remission in a way that will affect clinical practice. Histopathology may be the ultimate arbiter of mucosal healing. There is no agreement on the definition of remission in current guidelines. Patient-defined remission may predict endoscopic remission, but has yet to be shown to predict duration of remission.

CONCLUSIONS

A standard based on clinical symptoms and endoscopy is proposed. Histopathology is a third dimension of remission that may have prognostic value. The definition of remission should help predict long-term outcome. The expectations of patients and their physicians need to be raised, as the goal of treatment of active ulcerative colitis should be to induce remission.

摘要

背景

目前尚无用于衡量溃疡性结肠炎疾病活动度的评分系统的国际共识,也没有针对疾病缓解的验证定义。

目的

回顾溃疡性结肠炎缓解定义的原则和组成部分,并提出有助于改善患者结局的定义。

方法

作者从临床试验、指南、临床实践和患者的角度对缓解的现有标准进行了综述。根据现有定义,选择的文献重点关注缓解定义的组成部分、定义的实用性和治疗策略。

结果

不同的缓解定义会影响对结局的评估,且使试验之间难以进行比较。在临床上,内镜检查很少用于确认缓解,因为黏膜愈合最近才开始与随后缓解的持续时间相关,从而影响临床实践。组织病理学可能是黏膜愈合的最终仲裁者。目前的指南中没有关于缓解的定义达成共识。患者定义的缓解可能预测内镜缓解,但尚未证明能预测缓解的持续时间。

结论

提出了一种基于临床症状和内镜的标准。组织病理学是缓解的第三个维度,可能具有预后价值。缓解的定义应有助于预测长期结局。需要提高患者及其医生的期望,因为治疗活动性溃疡性结肠炎的目标应该是诱导缓解。

相似文献

1
Review article: defining remission in ulcerative colitis.综述文章:溃疡性结肠炎缓解的定义。
Aliment Pharmacol Ther. 2011 Jul;34(2):113-24. doi: 10.1111/j.1365-2036.2011.04701.x. Epub 2011 May 25.
2
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.英夫利昔单抗早期黏膜愈合与溃疡性结肠炎的长期临床结局改善相关。
Gastroenterology. 2011 Oct;141(4):1194-201. doi: 10.1053/j.gastro.2011.06.054. Epub 2011 Jun 30.
3
Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.溃疡性结肠炎临床试验中内镜反应和缓解的定义:一项国际共识
Aliment Pharmacol Ther. 2017 Mar;45(6):801-813. doi: 10.1111/apt.13948. Epub 2017 Jan 23.
4
Review article: the management of steroid dependency in ulcerative colitis.综述文章:溃疡性结肠炎中类固醇依赖的管理
Aliment Pharmacol Ther. 2007 Sep 15;26(6):779-94. doi: 10.1111/j.1365-2036.2007.03334.x.
5
The role of endoscopic assessment in ulcerative colitis in the era of infliximab.英夫利昔单抗时代内镜评估在溃疡性结肠炎中的作用
Dig Liver Dis. 2008 Jul;40 Suppl 2:S220-4. doi: 10.1016/S1590-8658(08)60529-0.
6
Mucosal healing as a treatment for IBD?黏膜愈合作为炎症性肠病的一种治疗方法?
Expert Rev Gastroenterol Hepatol. 2014 Jul;8(5):457-9. doi: 10.1586/17474124.2014.902302. Epub 2014 Mar 22.
7
A review of infliximab use in ulcerative colitis.英夫利昔单抗在溃疡性结肠炎中的应用综述。
Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014.
8
Review article: the management of mild to severe acute ulcerative colitis.综述文章:轻度至重度急性溃疡性结肠炎的管理
Aliment Pharmacol Ther. 2004 Oct;20 Suppl 4:88-92. doi: 10.1111/j.1365-2036.2004.02056.x.
9
Endomicroscopy for assessing mucosal healing in patients with ulcerative colitis.内镜黏膜成像评估溃疡性结肠炎患者的黏膜愈合情况。
J Gastrointestin Liver Dis. 2011 Dec;20(4):423-6.
10
Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.英夫利昔单抗作为他克莫司治疗抵抗性溃疡性结肠炎的补救治疗的疗效和安全性。
J Gastroenterol Hepatol. 2010 May;25(5):886-91. doi: 10.1111/j.1440-1746.2009.06206.x.

引用本文的文献

1
Asia Pacific association of gastroenterology consensus statements on histopathological evaluation of inflammatory bowel diseases.亚太胃肠病学协会关于炎症性肠病组织病理学评估的共识声明
Therap Adv Gastroenterol. 2025 Aug 19;18:17562848251363703. doi: 10.1177/17562848251363703. eCollection 2025.
2
Impact of Obesity on the Long-Term Outcomes of Advanced Therapies in IBD: A Real-World Study in Taiwan.肥胖对炎症性肠病高级疗法长期疗效的影响:台湾的一项真实世界研究
J Inflamm Res. 2025 Jun 3;18:7139-7149. doi: 10.2147/JIR.S520446. eCollection 2025.
3
Pathology assessment of inflammatory bowel disease - prospective study from two referral centers.
炎症性肠病的病理学评估——来自两个转诊中心的前瞻性研究
Rom J Morphol Embryol. 2025 Jan-Mar;66(1):205-215. doi: 10.47162/RJME.66.1.19.
4
Irritable Bowel Syndrome-like Symptoms in Patients With Ulcerative Colitis in Remission as Compared to Irritable Bowel Syndrome: Symptom Severity and Inflammatory Markers.溃疡性结肠炎缓解期患者与肠易激综合征患者的肠易激综合征样症状:症状严重程度及炎症标志物
J Neurogastroenterol Motil. 2025 Jul 30;31(3):313-320. doi: 10.5056/jnm24010. Epub 2025 Apr 28.
5
Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stability.轻度至中度哮喘的临床缓解:发生率、影响因素及稳定性
J Allergy Clin Immunol Glob. 2025 Jan 30;4(2):100431. doi: 10.1016/j.jacig.2025.100431. eCollection 2025 May.
6
Immunohistochemistry Analysis in Inflammatory Bowel Disease-Should We Bring to Light Interleukin-10?炎症性肠病中的免疫组织化学分析——我们应该揭示白细胞介素-10吗?
Biomedicines. 2025 Feb 7;13(2):406. doi: 10.3390/biomedicines13020406.
7
Transcriptomic Insights into the Molecular Mechanisms of Indole Analogues from the Extract and Their Therapeutic Effects on Ulcerative Colitis.从提取物中获得的吲哚类似物的分子机制的转录组学见解及其对溃疡性结肠炎的治疗作用
Animals (Basel). 2024 Dec 30;15(1):63. doi: 10.3390/ani15010063.
8
On-treatment clinical remission of severe asthma with real-world longer-term biologic use.在现实世界中长期使用生物制剂治疗重度哮喘的治疗期临床缓解情况。
J Allergy Clin Immunol Glob. 2024 Oct 30;4(1):100365. doi: 10.1016/j.jacig.2024.100365. eCollection 2025 Feb.
9
Unveiling the efficacy of paroxetine and gabapentin in ulcerative colitis patients in remission with co-existing IBS-like symptoms: a single-blinded randomized clinical trial.揭示帕罗西汀和加巴喷丁对伴有肠易激综合征样症状的缓解期溃疡性结肠炎患者的疗效:一项单盲随机临床试验。
Front Med (Lausanne). 2024 Nov 20;11:1468885. doi: 10.3389/fmed.2024.1468885. eCollection 2024.
10
Absence of Paneth Cell Metaplasia to Predict Clinical Relapse in Ulcerative Colitis with Endoscopically Quiescent Mucosa.在内镜下黏膜静止的溃疡性结肠炎中,缺乏帕内特细胞化生可预测临床复发。
Dig Dis Sci. 2024 Oct;69(10):3932-3941. doi: 10.1007/s10620-024-08581-9. Epub 2024 Aug 7.